Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for breast cancer and other breast health conditions. The company’s work centers on oncology, with an emphasis on hormone-driven disease areas and related unmet medical needs. Its current pipeline includes investigational medicines and therapeutic programs designed to address breast cancer prevention and treatment, as well as selected rare diseases where estrogen-related biology may be relevant. Atossa Therapeutics also advances diagnostic capabilities connected to breast health, supporting a broader approach to disease management. Based in Seattle, Washington, the company operates within the biotechnology sector and plays a role in translating research into potential treatment options for women’s health and cancer care.
Website448 NW Market Street
Seattle, WA, 98107
United States
Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company, today announced that Steven Quay, M.D., Ph.D., Atossa's President and Chief Executive Officer, will participate as a panelist at the 13th Aging Research and Drug Discovery Meeting (ARDD 2026), being held October 1–3, 2026, at the David Rubenstein Treehouse at Harvard University in Boston, MA.
Tipranks Press Release.
Detailed price information for Perspective Therapeutics Inc (CATX-A) from The Globe and Mail including charting and trades.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced its financial results and provided an update on recent corporate developments for the second quarter ended June 30, 2026.
Investors talking about ATOS also mention
What share of all stock conversation is about ATOS?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% 0 | 0% +0 | 0% 0 | 0% -0.01 |
Of the messages about ATOS that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | 50% new | 12.5% -87.5 | 70.37% +2.19 | 67.13% -4.66 | ||
| Bearish | 50% -50 | 87.5% new | 29.63% -2.19 | 32.87% +4.66 |
Of the messages about ATOS that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | — | — | 56.67% | 29.3% | ||
| Analysts | — | — | 0% | 27.69% | ||
| Technical Analysis | — | — | 0% | 33.49% | ||
| Controversies | — | — | 43.33% | 2.44% | ||
| Earnings | — | — | 0% | 0.41% | ||
| Macro | — | — | 0% | 6.66% |
Of the messages about ATOS, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | 100% | 100% | 88.71% | 87.86% | ||
| Newcomers | 0% | 0% | 11.29% | 12.14% |